Author

Mark A. Daniëls

University of MissouriORCID 0000-0002-5175-9901Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Brian J. ThomasiD· 2 shared Donald H. BurkeiD· 2 shared Benjamin J. CryeriD· 1 shared David PorcianiiD· 1 shared Lee‐Ann H. AlleniD· 1 shared Margaret J. LangeiD· 1 shared Sania Zafar Awan· 1 shared Sydney M. EscobariD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Brian J. ThomasORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

DUSP11 is an intracellular innate immune checkpoint in lung adenocarcinoma

Brian J. Thomas, Xue Bai, Benjamin J. Cryer, Sydney M. Escobar, Lee‐Ann H. Allen, Mark A. Daniëls, Margaret J. Lange, Donald H. Burke

This study identifies DUSP11 as an intracellular innate immune checkpoint in LUAD, showing its role in tumor survival and growth, and suggests it as a potential therapeutic target.

Cancer Immunology Research · Sep 4, 2025Peer-reviewedCancer Biology

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brian J. Thomas, Sania Zafar Awan, Trupti Joshi, Mark A. Daniëls, David Porciani, Donald H. Burke

This study shows that an anti-EGFR aptamer reduces viability of NSCLC cells with EGFR L858R mutations and tumor burden in a mouse model, with cell line-dependent mechanisms.

npj Precision Oncology · Nov 21, 2024Peer-reviewedCancer Biology